Always unpopular pointing this stuff out, but this is an absolutely horrific report. A clear case of management enriching themselves/employees at the expense of shareholders. Ignore the word salad in the first 15 pages and go straight to the numbers on the P&L statement, page 22 (remembering these are all in USD)
- Revenue down 30% from $3.9M to $2.7M (understandable given market conditions)
- Production costs down 64% from $2.7M to $1.0M (ostensibly good, but why are they spending so little on their products?)
- Admin costs only down 2.9% from $9.8M to $9.5M (wtaf, do they have gold-plated toilets?)
- Borrowing costs up 92% from $0.9M to $1.9M (understandable, but why do they have $63M in borrowings in the first place?)
- R&D spend down 11% from $2.2M to $2.0M (shouldn't they be spending more on R&D, not less?)
- Share based compensation down 30% from $6.8M to $4.7M (good but still huge numbers, and entirely offset by...)
- Employee expenses up 47% from $8.9M to $13.0M (so completely offsets any savings in the SBC above)
All in all they've trotted out an even larger loss ($28.7M) than the prior half year ($28.1M) despite spending far less on production and R&D costs, thanks predominantly to how much they pay themselves and their staff. The 'key highlights' paragraph claims they have "industry-leading R&D efforts for battery materials" yet they spent less on R&D than the prior year, but way more on employee costs. All the metrics are around the wrong way. Oh, and they have $63M in borrowings too....
And all of this is only for half a year. At this rate they'll be out of cash before you know it. A nice rort if you're in on it... shareholders sure aren't!
- Forums
- ASX - By Stock
- Ann: Half Yearly Report and Accounts
Always unpopular pointing this stuff out, but this is an...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NVX (ASX) to my watchlist
(20min delay)
|
|||||
Last
78.0¢ |
Change
-0.010(1.27%) |
Mkt cap ! $385.1M |
Open | High | Low | Value | Volume |
78.0¢ | 80.5¢ | 77.5¢ | $922.5K | 1.172M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 16461 | 78.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
78.5¢ | 2992 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 16461 | 0.780 |
3 | 55848 | 0.775 |
9 | 142248 | 0.770 |
11 | 143195 | 0.765 |
11 | 213697 | 0.760 |
Price($) | Vol. | No. |
---|---|---|
0.790 | 20603 | 2 |
0.795 | 43195 | 1 |
0.800 | 55352 | 4 |
0.805 | 50629 | 3 |
0.810 | 46100 | 3 |
Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
Featured News
NVX (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online